Franklin Resources Inc. Buys 73,323 Shares of Eli Lilly and Company $LLY

Franklin Resources Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 1.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,840,188 shares of the company’s stock after buying an additional 73,323 shares during the period. Eli Lilly and Company accounts for approximately 0.9% of Franklin Resources Inc.’s investment portfolio, making the stock its 14th biggest holding. Franklin Resources Inc. owned about 0.51% of Eli Lilly and Company worth $3,693,063,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after acquiring an additional 551,659 shares in the last quarter. Capital Research Global Investors raised its position in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Laurel Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $8,827,714,000. Finally, Capital International Investors grew its position in Eli Lilly and Company by 6.1% in the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock valued at $7,628,447,000 after purchasing an additional 579,381 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Cantor Fitzgerald boosted their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Scotiabank reaffirmed an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Bank of America reduced their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Trading Down 0.8%

NYSE:LLY opened at $1,000.30 on Wednesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a market cap of $943.64 billion, a price-to-earnings ratio of 43.59, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a 50-day moving average price of $1,042.64 and a two-hundred day moving average price of $946.71.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY is reportedly set to launch an oral obesity GLP‑1 in Q2, which would expand the market beyond injectables and support long‑term sales growth. Eli Lilly Set to Launch Oral Obesity Drug
• Positive Sentiment: The company launched an Employer Connect platform to broaden employer-sponsored access to obesity treatments, potentially increasing uptake and reducing access friction. Employer Connect Platform
• Positive Sentiment: Distribution gains: Amazon Pharmacy expanded access to LLY’s Zepbound KwikPen, improving retail availability and convenience for patients. Wider distribution should aid sales growth. Amazon Pharmacy Expands Access
• Positive Sentiment: Strategic and analyst support: LLY plans a $500M investment in South Korea’s biotech sector and J.P. Morgan reiterated a Buy rating — both signal management’s growth push and continued analyst confidence. South Korea Investment J.P. Morgan Keeps Buy Rating
• Neutral Sentiment: Macro/sector flow: crude-driven market moves and geopolitical tensions (Iran) have triggered sector rotation into aerospace and biopharma volatility; this broader rotation contributed to intraday pressure on LLY alongside other large-cap names. Sector Rotation Amid Geopolitics
• Negative Sentiment: Medicare coverage uncertainty: Eli Lilly warned some basic Medicare plans may not adhere to the $50/month out‑of‑pocket cap for weight‑loss drugs under the CMS model — this could complicate access and payer economics in the near term. Medicare Cap Warning
• Negative Sentiment: Legal risk: a U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to the older diabetes drug Actos, spotlighting potential liability and cash‑flow/legal exposure. Actos Class Action

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.